10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Therapies from Fucoidan: New Developments

      review-article
      * , , ,
      Marine Drugs
      MDPI
      fucoidan, microbiome, analysis, norovirus

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Since our last review in 2015, the study and use of fucoidan has extended in several research areas. Clinical use of fucoidan for the treatment of renal disease has become available and human safety studies have been undertaken on radiolabeled fucoidan for the purpose of imaging thrombi. Fucoidan has been incorporated into an increasing number of commercially available supplements and topical treatments. In addition, new measuring techniques are now available to assess the biologically relevant uptake of fucoidans and to assist in production. Microbiome modulation and anti-pathogenic effects are increasingly promising applications for fucoidans, due to the need for alternative approaches to antibiotic use in the food chain. This review outlines promising new developments in fucoidan research, including potential future therapeutic use.

          Related collections

          Most cited references84

          • Record: found
          • Abstract: found
          • Article: not found

          The intestinal microbiota fuelling metabolic inflammation

          Low-grade inflammation is the hallmark of metabolic disorders such as obesity, type 2 diabetes and nonalcoholic fatty liver disease. Emerging evidence indicates that these disorders are characterized by alterations in the intestinal microbiota composition and its metabolites, which translocate from the gut across a disrupted intestinal barrier to affect various metabolic organs, such as the liver and adipose tissue, thereby contributing to metabolic inflammation. Here, we discuss some of the recently identified mechanisms that showcase the role of the intestinal microbiota and barrier dysfunction in metabolic inflammation. We propose a concept by which the gut microbiota fuels metabolic inflammation and dysregulation.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy

            Checkpoint immunotherapy that inhibits tumour immune evasion has demonstrated significant clinical success. However, the therapeutic response is limited to certain patient populations, and immunotoxicity as well as autoimmunity have compromised the therapeutic benefits. Here, we report on an inherently therapeutic fucoidan-dextran-based magnetic nanomedicine (IO@FuDex3) conjugated with a checkpoint inhibitor (anti-PD-L1) and T-cell activators (anti-CD3 and anti-CD28). IO@FuDex3 can repair the immunosuppressive tumour microenvironment by reinvigorating tumour-infiltrating lymphocytes, while targeting the nanomedicine via magnetic navigation to the tumour to minimize off-target effects. Treatment that combines IO@FuDex3 and magnetic navigation reduces the occurrence of adverse events and extends the median survival from 32 to 63 days with less than 1 per cent dose compared with soluble anti-PD-L1. Thus, we demonstrate the potential of integrating anti-PD-L1 and T-cell activators as a form of inherently therapeutic nanomedicine to augment the therapeutic index of combination checkpoint immunotherapy.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Microbiota-gut brain axis involvement in neuropsychiatric disorders

                Bookmark

                Author and article information

                Journal
                Mar Drugs
                Mar Drugs
                marinedrugs
                Marine Drugs
                MDPI
                1660-3397
                09 October 2019
                October 2019
                : 17
                : 10
                : 571
                Affiliations
                Marinova Pty Ltd., 249 Kennedy Drive, Cambridge, Tasmania 7170, Australia; damien.stringer@ 123456marinova.com.au (D.N.S.); ahyoung.park@ 123456marinova.com.au (A.Y.P.); sam.karpiniec@ 123456marinova.com.au (S.S.K.)
                Author notes
                [* ]Correspondence: helen.fitton@ 123456marinova.com.au ; Tel.: +61-3-6248-5800
                Article
                marinedrugs-17-00571
                10.3390/md17100571
                6836154
                31601041
                222a3132-794b-4480-a125-8eaed29cbec5
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 30 August 2019
                : 06 October 2019
                Categories
                Review

                Pharmacology & Pharmaceutical medicine
                fucoidan,microbiome,analysis,norovirus
                Pharmacology & Pharmaceutical medicine
                fucoidan, microbiome, analysis, norovirus

                Comments

                Comment on this article